A pilot trial found medical cannabis feasible and potentially helpful for pain, appetite, and insomnia in pancreatic cancer patients | Research

The takeaway

A randomized pilot trial of 32 pancreatic cancer patients found medical cannabis was feasible through a state program partnership, with early-access patients showing numerically higher improvement rates in pain (44% vs 20%), appetite (56% vs 30%), and insomnia (67% vs 30%).

Oncologists, palliative care clinicians, cannabis researchers designing trials

Insomnia improved in 67% of early cannabis group vs. 30% of delayed group

What the researchers found

The trial met all prespecified feasibility benchmarks: 74% enrollment (goal 20%), 81% compliance (goal 60%), and 75% outcome completion (goal 50%). All early-arm participants recommended the intervention. At 8 weeks, early-arm patients showed numerically higher improvement rates for pain (44% vs 20%), appetite (56% vs 30%), and insomnia (67% vs 30%), though none reached statistical significance. Median daily THC use was 7.3 mg. Cannabis-related harms were low.

Why it matters

Pancreatic cancer patients experience severe symptom burden and limited treatment options. This study demonstrates that rigorous cannabis research can be conducted through state program partnerships, offering a path around federal regulatory barriers.

The numbers in context

32 patients; median age 71; 53% women; baseline symptom burden: insomnia 85%, pain 77%, appetite loss 69%; enrollment rate: 74%; compliance: 81%; outcome completion: 75%; median THC: 7.3 mg/day; pain improvement: 44% vs 20% (p = 0.35); appetite: 56% vs 30% (p = 0.37); insomnia: 67% vs 30% (p = 0.18)

How the study worked

Pilot randomized waitlist-controlled trial of 32 patients with newly diagnosed locally advanced/metastatic pancreatic adenocarcinoma in Minnesota. Randomized 1:1 to early (weeks 0-8) or delayed (weeks 9-16) cannabis intervention through the Minnesota Medical Cannabis Program. Primary outcome was feasibility.

What this study cannot tell us

Pilot study not powered for efficacy (32 patients). No differences reached statistical significance. Waitlist control, not placebo-controlled. Open-label design subject to expectation bias. Single state program may not generalize.

How to read the evidence

Preliminary: pilot feasibility trial not powered for efficacy, with open-label design and small sample. Valuable as proof-of-concept for state program partnerships.

When this study was published

2026 publication from a pilot RCT through the Minnesota Medical Cannabis Program.

The bigger picture

This pilot demonstrates a replicable model for conducting interventional cannabis research within existing state programs. If larger trials confirm these preliminary signals, medical cannabis could become part of supportive care for pancreatic cancer.

Questions still open

Would a larger, placebo-controlled trial confirm the symptom improvement signals? What cannabis products and doses are optimal for pancreatic cancer symptoms? Could medical cannabis reduce opioid requirements in this population?

Common questions

Can medical cannabis help pancreatic cancer patients?

This pilot trial showed promising signals: 67% improvement in insomnia, 56% in appetite, and 44% in pain among early cannabis users. However, the study was too small to confirm efficacy, and a larger trial is needed.

How was this trial possible given federal cannabis restrictions?

The researchers partnered with the Minnesota Medical Cannabis Program, using state-approved products and dispensaries. This model could be replicated in other states to overcome federal research barriers.

Read the original research

Pilot Randomized Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Newly Diagnosed Advanced Pancreatic Cancer (CanPan).

JCO oncology practice, OP2501165

View on PubMed ↗Publisher’s paper ↗

Citation

Zylla, Dylan; Chrenka, Ella; Lin, Kendall; Gilmore, Grace; Cowger, Jordan; Rak, David; Gupta, Arjun. (2026). Pilot Randomized Trial of Medical Cannabis to Reduce Symptom Burden in Patients With Newly Diagnosed Advanced Pancreatic Cancer (CanPan).. JCO oncology practice, OP2501165. https://doi.org/10.1200/OP-25-01165